RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31

RHYTHM PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$88.23+2.06 (+2.39%)

Close on Oct 19, 2026

Market cap: $6.05B
P/E (TTM): –
Dividend yield: –

RHYTHM PHARMACEUTICALS, INC. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31	TTM Q3 2017 2017-09-30	TTM FY 2016 2016-12-31
Depreciation & Amortization	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.82	1.01	0.87	0.72	0.69	0.70	0.72	0.76	0.83	0.86	0.77	0.63	0.44	0.29	0.24	0.23	0.22	0.22	0.14
Stock-Based Compensation	87	77	67	58	50	45	40	38	35	34	33	29	25	22	20	19	20	20	21	20	20	17	17	16	14	15	12	11	9.83	8.08	6.39	5.08	4.05	2.97	2.28	1.88	1.17
Change in Accounts Receivable	-15	-16	-7.57	-13	-8.06	-3.13	-3.65	-4.77	-3.77	-6.58	-8.64	-11	-11	–	-5.20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Change in Inventory	-13	-9.99	-7.47	-7.39	-6.84	-11	-10	-6.13	-5.82	-3.02	-5.71	-6.08	-4.49	–	-2.81	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Change in Accounts Payable	23	20	22	36	32	20	22	12	8.18	8.36	15	26	8.97	6.76	1.54	-1.25	17	25	18	7.33	1.88	-6.04	-6.45	-8.92	-11	5.91	11	17	19	6.10	6.95	2.34	2.30	1.19	1.95	1.33	0.16
Change in Unearned Revenue	0	0.05	-1.09	–	–	–	–	–	–	–	-0.15	-7.23	-7.78	–	-6.61	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.25
Operating Cash Flow	-105	-120	-116	-109	-108	-113	-114	-124	-128	-140	-136	-141	-159	-156	-173	-180	-173	-166	-146	-135	-122	-119	-122	-125	-132	-127	-123	-112	-95	-82	-62	-49	-40	-34	-29	-28	-23
Capital Expenditures	–	–	–	–	–	–	–	–	–	–	-0.05	-0.05	-0.14	-0.20	-0.28	-0.35	-0.36	-0.55	-0.43	-0.45	–	–	-0.21	–	–	–	-3.39	-3.78	-3.84	–	-0.72	–	–	–	-0.13	–	-1.06
Purchase of Investments	-374	-357	-349	-395	-262	–	-268	–	–	–	-355	-415	-347	-282	-252	-220	-213	-267	-525	-490	-406	-369	-87	-238	-269	-255	-296	-171	-298	-302	-249	-302	-134	-117	-127	-17	-15
Investing Cash Flow	-145	-105	-137	-146	9.19	-53	-48	-47	-51	5.92	-5.67	-69	-14	-26	28	76	179	156	-62	-7.52	-35	-16	159	-42	-36	-23	-28	123	-55	-84	-87	-211	-68	-81	-110	1.51	-5.11
Stock Issued	–	–	–	–	–	–	–	–	–	–	49	–	–	–	131	–	–	–	162	–	–	–	–	–	–	–	–	–	–	–	163	–	–	–	–	–	–
Debt Issued	–	–	–	–	–	–	–	–	–	–	24	–	–	–	72	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Debt Repaid	-22	-20	-20	-18	-16	-15	-13	-12	-10	-8.83	-7.40	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Financing Cash Flow	180	180	218	259	72	219	191	155	226	79	74	89	175	213	214	197	38	1.30	166	167	167	167	2.01	164	164	164	163	1.66	2.14	–	165	–	–	–	167	–	–
Foreign Exchange Rate Adjustments	0.60	0.54	0.09	1.00	0.09	0.07	0.00	-1.17	-0.49	-0.30	-0.14	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Change in Cash	-70	-44	-35	4.77	-26	53	29	-17	46	-56	-68	-120	2.48	31	68	93	44	-8.73	-42	25	10	31	39	-4.01	-4.03	14	13	14	-147	-1.00	15	30	202	31	28	15	-28
Free Cash Flow	–	–	–	–	–	–	–	–	–	–	-136	-141	-159	-156	-174	-180	-173	-167	-146	-135	–	–	-122	–	–	–	-126	-115	-99	–	-63	–	–	–	-30	–	-24

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 89.0%
Operating margin: -83.6%
Net margin: -85.6%
Return on equity, FY2025: -244.5%

Financial strength

Current ratio: 3.45
Debt to equity: 1.03
Debt to assets: 24.3%
Cash to current liabilities: 53.1%

Valuation

P/E ratio: –
Price to sales: 25.22
Price to book: 58.77
Dividend yield: –